Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report
Case Reports in Ophthalmology · 07.09.2026 · 17 (1) · 980-987
DOI: 10.1159/cop/acaag008 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Ophthalmology, online erschienen am 07.09.2026. Verfasst von Hinrich J Hufnagel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, B…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Choroidal metastases may cause substantial visual impairment in patients with metastatic non-small cell lung cancer (NSCLC). Although local ocular treatments are frequently considered, targeted systemic therapy may provide effective control in tumors harboring actionable mutations. We report the rapid regression of a choroidal metastasis following first-line osimertinib therapy in a patient with epidermal growth factor receptor (EGFR)-mutated NSCLC. Case Presentation: A 59-year-old man with metastatic EGFR-mutated NSCLC presented with progressive visual decline in the left eye. Ophthalmic examination revealed a peripapillary choroidal lesion associated with serous retinal detachment. Optical coherence tomography demonstrated subretinal fluid, consistent with a choroidal metastasis. First-line osimertinib therapy had been initiated 12 days before presentation at our clinic. An early reduction in subretinal fluid was observed during follow-up, followed by complete resolution at the 2-month follow-up. This was accompanied by regression of the choroidal lesion and improvement in visual function. No local ocular treatment was required.
Conclusion
First-line osimertinib may induce rapid regression of choroidal metastases in patients with EGFR-mutated NSCLC. In selected cases, an early response to systemic targeted therapy may allow local ocular treatment to be avoided.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Ophthalmology, Medizinische Universität Lausitz - Carl Thiem, Cottbus, Germany.
Zitieren
APA
Hufnagel, H. J., Zeitz, O., Abdula, F., Joussen, A. M., & Zur Bonsen, L. S. (2026). Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report. Case Reports in Ophthalmology, 17(1), 980-987. https://doi.org/10.1159/cop/acaag008
Vancouver
Hufnagel HJ, Zeitz O, Abdula F, Joussen AM, Zur Bonsen LS. Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report. Case Reports in Ophthalmology. 2026;17(1):980-987. doi:10.1159/cop/acaag008
BibTeX
@article{Hufnagel2026,
author = {Hufnagel, Hinrich J and Zeitz, Oliver and Abdula, Farris and Joussen, Antonia M and Zur Bonsen, Lynn S},
title = {Rapid Regression of Choroidal Metastasis under First-Line Osimertinib Therapy in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Case Report},
journal = {Case Reports in Ophthalmology},
year = {2026},
volume = {17},
number = {1},
pages = {980--987},
doi = {10.1159/cop/acaag008}
}
EUVIMED